Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.51 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.51 |
| ▸ | HPGD | P15428 | 3/20 | 0.51 |
| ▸ | RXFP1 | Q9HBX9 | 2/20 | 0.51 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.51 |
| ▸ | CASP1 | P29466 | 2/20 | 0.51 |
| ▸ | CASP7 | P55210 | 2/20 | 0.51 |
| ▸ | GAA | P10253 | 1/20 | 0.51 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.51 |
| ▸ | POLB | P06746 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.46 |
| ▸ | CLK1 | P49759 | 1/20 | 0.45 |
| ▸ | MAPK1 | P28482 | 3/20 | 0.44 |
| ▸ | TSHR | P16473 | 3/20 | 0.44 |
| ▸ | KHK | P50053 | 1/20 | 0.43 |
| ▸ | HTT | P42858 | 3/20 | 0.42 |
| ▸ | NSD2 | O96028 | 1/20 | 0.42 |
| ▸ | LMNA | P02545 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 1/20 | 0.42 |
| ▸ | CASP6 | P55212 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30206264 | 1.00 | ALDH1A1 (0.51) | ALDH1A1KDM4EHPGDRXFP1HSD17B10 | |
| SCHEMBL22996455 | 0.86 | CNR2 (0.50) | ALDH1A1KDM4EHPGDRXFP1HSD17B10 | |
| SCHEMBL19343217 | 0.84 | CNR2 (0.52) | ALDH1A1KDM4EHPGDRXFP1HSD17B10 | |
| SCHEMBL30852546 | 0.82 | ALDH1A1 (0.51) | ALDH1A1KDM4EHPGDRXFP1HSD17B10 | |
| SCHEMBL22561873 | 0.82 | ALDH1A1 (0.51) | ALDH1A1KDM4EHPGDRXFP1HSD17B10 | |
| SCHEMBL19997592 | 0.82 | KMT2A (0.52) | ALDH1A1KDM4EHPGDRXFP1HSD17B10 | |
| SCHEMBL14923786 | 0.82 | ALDH1A1 (0.51) | ALDH1A1KDM4EHPGDRXFP1HSD17B10 | |
| SCHEMBL25931435 | 0.81 | LRRK2 (0.44) | ALDH1A1KDM4EHPGDRXFP1HSD17B10 | |
| SCHEMBL18837991 | 0.78 | CNR2 (0.43) | ALDH1A1KDM4EHPGDRXFP1CASP1 | |
| SCHEMBL20796810 | 0.78 | ALDH1A1 (0.48) | ALDH1A1KDM4EHPGDRXFP1HSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2022066917-A1 | 3-(6-AMINOPYRIDIN-3-YL)BENZAMIDE DERIVATIVES AS RIPK2 INHIBITORS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2022-03-31 | — | — | WO | disclosed |
| EP-3191467-B1 | COMPOUNDS AND COMPOSITIONS AS KINASE INHIBITORS | NOVARTIS AG (CH) | 2020-10-21 | — | — | EP | disclosed |
| EP-3191467-B1 | COMPOUNDS AND COMPOSITIONS AS KINASE INHIBITORS | NOVARTIS AG (CH) | 2020-10-21 | — | — | EP | disclosed |
| US-10392404-B2 | Compounds and compositions as kinase inhibitors | NOVARTIS AG (CH) | 2019-08-27 | — | — | US | disclosed |
| US-10392404-B2 | Compounds and compositions as kinase inhibitors | NOVARTIS AG (CH) | 2019-08-27 | — | — | US | disclosed |
| US-10160763-B2 | WDR5 inhibitors and modulators | VANDERBILT UNIVERSITY (US) | 2018-12-25 | — | — | US | disclosed |
| EP-2589592-B1 | NOVEL NICOTINAMIDE DERIVATIVES OR SALTS THEREOF | FUJIFILM CORP (JP) | 2018-08-22 | — | — | EP | disclosed |
| US-20180086767-A1 | WDR5 INHIBITORS AND MODULATORS | VANDERBILT UNIVERSITY | 2018-03-29 | — | — | US | disclosed |
| US-20180086767-A1 | WDR5 INHIBITORS AND MODULATORS | VANDERBILT UNIVERSITY | 2018-03-29 | — | — | US | disclosed |
| US-20170260200-A1 | COMPOUNDS AND COMPOSITIONS AS KINASE INHIBITORS | NOVARTIS VACCINES AND DIAGNOSTICS, INC. | 2017-09-14 | — | — | US | disclosed |
| US-8809371-B2 | — | — | 2014-08-19 | — | — | US | disclosed |
| US-8809371-B2 | — | — | 2014-08-19 | — | — | US | disclosed |
| US-8809371-B2 | — | — | 2014-08-19 | — | — | US | disclosed |
| US-8772320-B2 | — | — | 2014-07-08 | — | — | US | disclosed |
| US-20130116430-A1 | NOVEL NICOTINAMIDE DERIVATIVE OR SALT THEREOF | FUJIFILM CORPORATION (JP) | 2013-05-09 | — | — | US | disclosed |
| US-20130116430-A1 | NOVEL NICOTINAMIDE DERIVATIVE OR SALT THEREOF | FUJIFILM CORPORATION (JP) | 2013-05-09 | — | — | US | disclosed |
| US-20130116430-A1 | NOVEL NICOTINAMIDE DERIVATIVE OR SALT THEREOF | FUJIFILM CORPORATION (JP) | 2013-05-09 | — | — | US | disclosed |
| EP-2589592-A1 | NOVEL NICOTINAMIDE DERIVATIVES OR SALTS THEREOF | FUJIFILM Corporation (JP) | 2013-05-08 | — | — | EP | disclosed |
| EP-2589592-A1 | NOVEL NICOTINAMIDE DERIVATIVES OR SALTS THEREOF | FUJIFILM Corporation (JP) | 2013-05-08 | — | — | EP | disclosed |
| WO-2012002577-A1 | NOVEL NICOTINAMIDE DERIVATIVES OR SALTS THEREOF | 富士フイルム株式会社 (JP) | 2012-01-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180086767-A1 | WDR5 INHIBITORS AND MODULATORS | WDR5, WDR1, WDR77 | ALDH1A1 3489/4885KDM4E 101/4885HPGD 3772/4885 |
| US-20170260200-A1 | COMPOUNDS AND COMPOSITIONS AS KINASE INHIBITORS | BRAF, RAF1, MAP3K20 | ALDH1A1 2822/4885KDM4E 1770/4885HPGD 2767/4885 |
| US-20130116430-A1 | NOVEL NICOTINAMIDE DERIVATIVE OR SALT THEREOF | SYK, CD38, BTK | ALDH1A1 1638/4885KDM4E 2420/4885HPGD 1481/4885 |
| US-10160763-B2 | WDR5 inhibitors and modulators | WDR5, WDR1, WDR77 | ALDH1A1 3489/4885KDM4E 101/4885HPGD 3772/4885 |
| US-10392404-B2 | Compounds and compositions as kinase inhibitors | BRAF, RAF1, MAP3K20 | ALDH1A1 2822/4885KDM4E 1770/4885HPGD 2767/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.